# US 2026/0091023 A1 · Gel-chewable dosage form

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091023 A1
- Document ID: US20260091023A1
- Status: Published application
- Kind: A1
- Application number: 19/412,073
- Filed: 2025-12-08
- Published: 2026-04-02
- Earliest claimed: 2019-09-27
- Assignees: Kenvue Brands LLC
- Applicants: Kenvue Brands LLC
- Inventors: Vipul DAVE; Anurag PANDEY
- Web page: https://patentgrep.com/patent/US20260091023A1

## CPC

- A61K 31/426: 1,3-Thiazoles
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/4164: 1,3-Diazoles
- A61K 31/4453: only substituted in position 1, e.g. propipocaine, diperodon
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/08: Oxides; Hydroxides
- A61K 33/10: Carbonates; Bicarbonates
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a gel-chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the gel-chewable dosage form and wherein the gel-chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the gel-chewable dosage form.

## Claims

### Claim 1

A gel-chewable dosage form comprising:
a gelling agent at a level of from 0.1 percent to 10 percent of the weight of the gel-chewable dosage form, wherein the gelling agent is selected from the group consisting of gelatin, pectin, kappa carrageenan, iota carrageenan and a combination of kappa and iota carrageenan;
a first active pharmaceutical ingredient that is encapsulated in a lipid material/matrix; the first active pharmaceutical ingredient comprises at least one histamine H2 receptor antagonist, and the H2 receptor antagonist is famotidine,
wherein the lipid encapsulated active pharmaceutical ingredient is embedded in the gel-chewable dosage form,
wherein the lipid material/matrix comprises a first lipid and a second lipid and the first lipid is plasticized with a plasticizer to match the texture of the gel-chewable matrix, wherein a difference in texture between the lipid material/matrix and the gel chewable dosage form as determined through analysis of force over time has a force-over-time total area difference of less than 10000 g/sec,
wherein the first lipid material is selected from the group consisting of fatty acid esters, phospholipids, waxes, fats and free fatty acids and their salts, and
wherein the gel-chewable dosage form comprises at least a second active pharmaceutical ingredient.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The gel-chewable dosage form according to claim 1, wherein the H2 receptor antagonist is famotidine and the second active pharmaceutical ingredient is at least one antacid.

### Claim 5 (depends on 1)

The gel-chewable dosage form according to claim 1, wherein the famotidine is liquid encapsulated famotidine, and wherein the particle size of the lipid encapsulated famotidine is from about 100 microns to about 5000 microns, such as from about 200 microns to about 2000 microns.

### Claim 6 (depends on 4)

The gel-chewable dosage form according to claim 4, wherein the at least one antacid is selected from the group consisting of calcium carbonate, sodium bicarbonate, magnesium hydroxide, aluminum hydroxide, aluminum oxide, magnesium oxide, magnesium carbonate, aluminum phosphate, magaldrate and magnesium trisilicate or mixtures thereof.

### Claim 7 (depends on 1)

The gel-chewable dosage form according to claim 1, wherein the lipid material is selected from the group consisting of Cetostearyl alcohol, Glyceryl dibehenate, mono/diglycerides, hydrogenated vegetable oil and vegetable oil or mixtures thereof.

### Claim 8 (depends on 1)

The gel-chewable dosage form according to claim 1, wherein the famotidine is a granulate, bead or compressed tablet, pellets or minitablettes.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The gel-chewable dosage form according to claim 1, wherein the plasticizer is medium-chain triglycerides (MCT) oil ranging from about 5 to about 50% by weight of the lipid material.

### Claim 11 (depends on 1)

The gel-chewable dosage form according to claim 1, further comprising a third active pharmaceutical ingredient, wherein the third active pharmaceutical ingredient comprises simethicone.

### Claim 12 (depends on 1)

The gel-chewable dosage form according to claim 1, further comprising at least one ingredient selected from the list consisting of a color, a flavor, a sweetener, a thickener, an emulsifier, an antioxidant, a preservative, a gelling agent and a disintegrant.

### Claim 13 (depends on 12)

The gel-chewable dosage form according to claim 12, wherein the flavor is selected from the group consisting of peppermint, spearmint, eucalyptus, licorice, vanilla, caramel, mixed berries, mixed fruits, black current, blue berry, cherry and lemon or mixtures thereof.

### Claim 14 (depends on 1)

The gel-chewable dosage form according to claim 1, wherein at least one of the first active pharmaceutical ingredient and the second active pharmaceutical ingredient is taste masked.

### Claim 15 (depends on 1)

The gel-chewable dosage form according to claim 1, wherein the famotidine is present in an amount of from about 2 to about 30 mg.

### Claim 16 (depends on 4)

The gel-chewable dosage form according to claim 4, wherein the antacid is present in an amount of from about 200 to about 3000 mg.

### Claim 17 (depends on 1)

A method of treatment of a subject suffering from a gastric disease or disorder by use of the gel-chewable dosage form according to claim 1.

### Claim 18 (depends on 1)

A method of treatment of a subject suffering from heart burn by use of the gel-chewable dosage form according to claim 1.
